{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,5,16]],"date-time":"2026-05-16T01:01:49Z","timestamp":1778893309967,"version":"3.51.4"},"reference-count":37,"publisher":"Springer Science and Business Media LLC","issue":"2","license":[{"start":{"date-parts":[[2019,1,9]],"date-time":"2019-01-09T00:00:00Z","timestamp":1546992000000},"content-version":"tdm","delay-in-days":0,"URL":"http:\/\/www.springer.com\/tdm"}],"funder":[{"name":"Janssen Pharmaceuticals, Germany","award":["ReCAP DRV-I-15-DEU-004-V03"],"award-info":[{"award-number":["ReCAP DRV-I-15-DEU-004-V03"]}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["J. Neurovirol."],"published-print":{"date-parts":[[2019,4]]},"DOI":"10.1007\/s13365-018-0701-x","type":"journal-article","created":{"date-parts":[[2019,1,9]],"date-time":"2019-01-09T09:11:28Z","timestamp":1547025088000},"page":"174-182","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":9,"title":["Simplification of combination antiretroviral therapy (cART) and the brain\u2014a real-life experience"],"prefix":"10.1007","volume":"25","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-9075-9402","authenticated-orcid":false,"given":"Gabriele","family":"Arendt","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Svenja","family":"Schlonies","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Eser","family":"Orhan","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Olaf","family":"St\u00fcve","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2019,1,9]]},"reference":[{"issue":"18","key":"701_CR1","doi-asserted-by":"publisher","first-page":"1789","DOI":"10.1212\/01.WNL.0000287431.88658.8b","volume":"69","author":"A Antinori","year":"2007","unstructured":"Antinori A, Arendt G, Becker JT, Brew BJ, Byrd DA, Cherner M, Clifford DB, Cinque P, Epstein LG, Goodkin K, Gisslen M, Grant I, Heaton RK, Joseph J, Marder K, Marra CM, McArthur JC, Nunn M, Price RW, Pulliam L, Robertson KR, Sacktor N, Valcour V, Wojna VE (2007) Updated research nosology for HIV-associated neurocognitive disorders (HAND). Neurology 69(18):1789\u20131799","journal-title":"Neurology"},{"issue":"6","key":"701_CR2","doi-asserted-by":"publisher","first-page":"362","DOI":"10.1007\/BF00315660","volume":"237","author":"G Arendt","year":"1990","unstructured":"Arendt G, Hefter H, Elsing C, Strohmeyer G, Freund HJ (1990) Motor dysfunction in HIV-infected patients without clinically detectable central-nervous deficit. J Neurol 237(6):362\u2013368","journal-title":"J Neurol"},{"issue":"7","key":"701_CR3","doi-asserted-by":"publisher","first-page":"581","DOI":"10.1016\/S1473-3099(14)70782-0","volume":"14","author":"JR Arribas","year":"2014","unstructured":"Arribas JR, Pialoux G, Gathe J, di Perri G, Reynes J, Tebas P, Nguyen T, Ebrahimi R, White K, Piontkowsky D (2014) Simplification to coformulated elvitegravir, cobicistat, emtricitabine, and tenofovir versus continuation of ritonavir-boosted protease inhibitor with emtricitabine and tenofovir in adults with virologically suppressed HIV (STRATEGY-PI): 48 week results of a randomised, open-label, phase 3b, non-inferiority trial. Lancet Infect Dis 14(7):581\u2013589","journal-title":"Lancet Infect Dis"},{"key":"701_CR4","doi-asserted-by":"publisher","first-page":"85","DOI":"10.1016\/S1473-3099(15)00096-1","volume":"15","author":"JR Arribas","year":"2015","unstructured":"Arribas JR, Girard PM, OLE\/RIS-EST13 Study Group et al (2015) Dual treatment with lopinavir-ritonavir plus lamivudine versus triple treatment with lopinavir-ritonavir plus lamivudine or emtricitabine and a second nucleos(t)ide reverse transcriptase inhibitor for maintenance of HIV-1 viral suppression (OLE): a randomised, open-label, non-inferiority trial. Lancet Infect Dis 15:85\u2013792","journal-title":"Lancet Infect Dis"},{"key":"701_CR5","doi-asserted-by":"publisher","first-page":"358","DOI":"10.1111\/hiv.12348","volume":"17","author":"JR Arribas","year":"2016","unstructured":"Arribas JR, Girard PM, Paton N, Winston A, Marcelin AG, Elbirt D, Hill A, Hadacek MB (2016) Efficacy of protease inhibitor monotherapy vs. triple therapy: meta-analysis of data from 2303 patients in 13 randomized trials. HIV Med 17:358\u2013367","journal-title":"HIV Med"},{"key":"701_CR6","doi-asserted-by":"publisher","first-page":"452","DOI":"10.1111\/hiv.12611","volume":"19","author":"A Borghetti","year":"2018","unstructured":"Borghetti A, Baldin G, Lombardi F, Ciccullo A, Capetti A, Rusconi S, Sterrantino G, Latini A, Cossu MV, Gagliardini R, de Luca A, di Giambenedetto S (2018) Efficacy and tolerability of lamivudine plus dolutegravir as a switch strategy in a multicentre cohort of patients with suppressed HIV-1 replication. HIV Med 19:452\u2013454. \n                    https:\/\/doi.org\/10.1111\/hiv.12611","journal-title":"HIV Med"},{"issue":"1","key":"701_CR7","doi-asserted-by":"publisher","first-page":"1","DOI":"10.7448\/IAS.20.01.21678","volume":"20","author":"P Cahn","year":"2017","unstructured":"Cahn P, Rol\u00f3n MJ et al (2017) Dolutegravir-lamivudine as initial therapy in HIV-1 infected, ARV-na\u00efve patients, 48-week results of the PADDLE(Pilot Antiretroviral Design with Dolutegravir LamivudinE) Study. J Int AIDS Soc 20(1):1\u20137","journal-title":"J Int AIDS Soc"},{"issue":"1","key":"701_CR8","doi-asserted-by":"publisher","first-page":"54","DOI":"10.2174\/1570162X13666150929112135","volume":"14","author":"A Calcagno","year":"2016","unstructured":"Calcagno A, Montrucchio C, Capetti A, Guaraldi G, Cenderello G, Calza L, Lanzafame M, Marinaro L, Tettoni MC, Trentini L, D'Avolio A, di Perri G, Bonora S (2016) Raltegravir plus nevirapine as maintenance antiretroviral therapy in HIV-positive patients: safety, Efficacy and Pharmacokinetics. Curr HIV Res 14(1):54\u201360","journal-title":"Curr HIV Res"},{"issue":"1","key":"701_CR9","doi-asserted-by":"publisher","first-page":"19","DOI":"10.1093\/jac\/dkw368","volume":"72","author":"V Calvez","year":"2017","unstructured":"Calvez V, Hocqueloux L, Meynard JL, Muret P, Castan B, Tardy JC, Peytavin G, Landman R (2017) Less-drug regimen including atazanavir in maintenance treatment of HIV infection: how, who, when, why? J Antimicrob Chemother 72(1):19\u201328","journal-title":"J Antimicrob Chemother"},{"issue":"5","key":"701_CR10","doi-asserted-by":"publisher","first-page":"352","DOI":"10.1080\/23744235.2017.1410285","volume":"50","author":"L Calza","year":"2018","unstructured":"Calza L, Cafaggi M, Colangeli V, Borderi M, Barchi E, Lanzafame M, Nicole\u2019 S, Degli Antoni AM, Bon I, Re MC, Viale P (2018) Simplification to dual-therapy containing lamivudine and darunavir\/ritonavir or atazanavir\/ritonavir in HIV-infected patients on virologically suppressive antiretroviral therapy. Infect Dis (Lond) 50(5):352\u2013360","journal-title":"Infect Dis (Lond)"},{"issue":"1","key":"701_CR11","doi-asserted-by":"publisher","first-page":"658","DOI":"10.1186\/s12879-017-2755-4","volume":"17","author":"AF Capetti","year":"2017","unstructured":"Capetti AF, Cossu MV, Orofino G, Sterrantino G, Cenderello G, de Socio GV, Cattelan AM, Soria A, Rusconi S, Riccardi N, Baldin GM, Niero FP, Barbarini G, Rizzardini G (2017) A dual regimen of ritonavir\/darunavir plus dolutegravirfor rescue or simplification of rescue therapy: 48 weeks\u2019observational data. BMC Infect Dis 17(1):658","journal-title":"BMC Infect Dis"},{"key":"701_CR12","doi-asserted-by":"publisher","first-page":"143","DOI":"10.1097\/QAI.0b013e318252f97e","volume":"60","author":"D Carey","year":"2012","unstructured":"Carey D, Pett S et al (2012) A randomized study of pharmacokinetics, efficacy, and safety of 2 raltegravir plus atazanavir strategies in ART-treated adults. J Acquir Immune Defic Syndr 60:143\u2013149","journal-title":"J Acquir Immune Defic Syndr"},{"key":"701_CR13","doi-asserted-by":"publisher","DOI":"10.7448\/IAS.17.4.19808","volume":"17","author":"M Fabbiani","year":"2014","unstructured":"Fabbiani M, di Giambenedetto S, Quiros-Roldan E, Latini A, Vullo V, Antinori A, Castagna A, Orofino G, Francisci D, Grilli E, Madeddu G, Grima P, Rusconi S, del Pin B, Mondi A, Borghetti A, Foc\u00e0 E, Colafigli M, de Luca A, Cauda R (2014) Simplification to atazanavir\/ritonavir+lamivudine in virologically suppressed HIV-infected patients: 24-weeks interim analysis from ATLAS-M trial. J Int AIDS Soc 17:19808","journal-title":"J Int AIDS Soc"},{"issue":"1","key":"701_CR14","doi-asserted-by":"publisher","first-page":"78","DOI":"10.1055\/s-0034-1372345","volume":"34","author":"F Ferretti","year":"2014","unstructured":"Ferretti F, Gianotti N, Lazzarin A, Cinque P (2014) Central nervous system HIV infection in \u201cless-drug regimen\u201d antiretroviral therapy simplification strategies. Semin Neurol 34(1):78\u201388","journal-title":"Semin Neurol"},{"issue":"12","key":"701_CR15","doi-asserted-by":"publisher","first-page":"838","DOI":"10.3109\/00365548.2014.947318","volume":"46","author":"P Gantner","year":"2014","unstructured":"Gantner P, Koeppel C, Partisani M, Batard ML, Bernard-Henry C, Cheneau C, de Mautort E, Priester M, Muret P, Sueur C, Fafi-Kremer S, Rey D (2014) Efficacy and safety of switching to raltegravir plus atazanavir dual therapy in pretreated HIV-1-infected patients over 144 weeks: a cohort study. Scan J Infect Dis 46(12):838\u2013845","journal-title":"Scan J Infect Dis"},{"issue":"3","key":"701_CR16","doi-asserted-by":"publisher","first-page":"654","DOI":"10.1002\/1097-4679(197607)32:3<654::AID-JCLP2270320336>3.0.CO;2-Z","volume":"32","author":"CJ Golden","year":"1976","unstructured":"Golden CJ (1976) Identification of brain disorders by the Stroop Colour and Word Test. J Clin Psychol 32(3):654\u2013658","journal-title":"J Clin Psychol"},{"key":"701_CR17","doi-asserted-by":"publisher","first-page":"391","DOI":"10.1007\/s13365-018-0626-4","volume":"24","author":"A Imaz","year":"2018","unstructured":"Imaz A, Niub\u00f3 J, Amara A, Khoo S, Ferrer E, Tiraboschi JM, Acerete L, Garcia B, Vila A, Podzamczer D (2018) Cerebrospinal fluid drug concentrations and viral suppression in HIV-1-infected patients receiving ritonavir-boosted atazanavir plus lamivudine dual antiretroviral therapy (Spanish HIV\/AIDS Research Network, PreEC\/RIS 39). J Neurovirol 24:391\u2013397. \n                    https:\/\/doi.org\/10.1007\/s13365-018-0626-4","journal-title":"J Neurovirol"},{"issue":"9","key":"701_CR18","doi-asserted-by":"publisher","first-page":"795","DOI":"10.1056\/NEJMoa1506816","volume":"373","author":"JD Lundgren","year":"2015","unstructured":"INSIGHT START Study Group, Lundgren JD, Babiker AG et al (2015) Initiation of antiretroviral therapy in early asymptomatic HIV infection. N Engl J Med 373(9):795\u2013807","journal-title":"N Engl J Med"},{"key":"701_CR19","volume-title":"The medical clinics of North America","author":"H Klove","year":"1963","unstructured":"Klove H (1963) Clinical neuropsychology. In: Foster FM (ed) The medical clinics of North America. Saunders, New York"},{"issue":"1","key":"701_CR20","doi-asserted-by":"publisher","first-page":"65","DOI":"10.1001\/archneurol.2007.31","volume":"65","author":"S Letendre","year":"2008","unstructured":"Letendre S, Marquie-Beck J, Capparelli E, Best B, Clifford D, Collier AC, Gelman BB, McArthur J, McCutchan J, Morgello S, Simpson D, Grant I, Ellis RJ, CHARTER Group (2008) Validation of the CNS penetration-effectiveness rank for quantifying antiretroviral penetration into the central nervous system. Arch Neurol 65(1):65\u201370","journal-title":"Arch Neurol"},{"key":"701_CR21","unstructured":"Letendre SL, FitzSimons C et al (2010). Correlates of CSF viral loads in 1221 volunteers of the CHARTER cohort. 17th Conference on Retroviruses and opportunistic Infections (CROI) Montreal. Abstrno: 172"},{"key":"701_CR22","doi-asserted-by":"crossref","unstructured":"Maggiolo F, Di Filippo E et al (2016) NRTI sparing therapy in virologically controlled HIV-1 infected subjects: Results of a Controlled, Randomized Trail (Probe). J Acquir Immune Defic Syndr 72(1):46\u201351","DOI":"10.1097\/QAI.0000000000000966"},{"key":"701_CR23","doi-asserted-by":"publisher","first-page":"215","DOI":"10.1186\/s12879-017-2311-2","volume":"17","author":"F Maggiolo","year":"2017","unstructured":"Maggiolo F, Gulminetti R, Pagnucco L, Digaetano M, Benatti S, Valenti D, Callegaro A, Ripamonti D, Mussini C (2017) Lamivudine\/dolutegravir dual therapy in HIV-infected, virologically suppressed patients. BMC Infect Dis 17:215","journal-title":"BMC Infect Dis"},{"issue":"11","key":"701_CR24","doi-asserted-by":"publisher","first-page":"1697","DOI":"10.1097\/QAD.0b013e32833a608a","volume":"24","author":"E Mart\u00ednez","year":"2010","unstructured":"Mart\u00ednez E, Larrousse M, Llibre JM, Guti\u00e9rrez F, Saumoy M, Antela A, Knobel H, Murillas J, Berenguer J, Pich J, P\u00e9rez I, Gatell JM, SPIRAL Study Group (2010) Substitution of raltegravir for ritonavir-boosted protease inhibitors in HIV-infected patients: the SPIRAL study. AIDS 24(11):1697\u20131707","journal-title":"AIDS"},{"issue":"4","key":"701_CR25","doi-asserted-by":"publisher","first-page":"552","DOI":"10.1097\/FTD.0b013e31828d50ef","volume":"35","author":"M Mart\u00ednez-Rebollar","year":"2013","unstructured":"Mart\u00ednez-Rebollar M, Mu\u00f1oz A, P\u00e9rez I, Hidalgo S, Brunet M, Laguno M, Gonz\u00e1lez A, Calvo M, Lonc\u00e0 M, Blanco JL, Mart\u00ednez E, Gatell JM, Mallolas J (2013) Pharmacokinetic study of dual therapy with raltegravir 400 mg twice daily and darunavir\/ritonavir 800\/100 mg once daily in HIV-1-infected patients. Ther Drug Monit 35(4):552\u2013556","journal-title":"Ther Drug Monit"},{"issue":"7","key":"701_CR26","doi-asserted-by":"publisher","first-page":"1004","DOI":"10.1093\/cid\/cis975","volume":"56","author":"Mind Exchange Working Group","year":"2013","unstructured":"Mind Exchange Working Group (2013) Assessment, diagnosis, and treatment of HIV-associated neurocognitive disorder: a consensus report of the mind exchange program. Clin Infect Dis 56(7):1004\u20131017","journal-title":"Clin Infect Dis"},{"key":"701_CR27","doi-asserted-by":"publisher","first-page":"1843","DOI":"10.1093\/jac\/dkv037","volume":"70","author":"A Mondi","year":"2015","unstructured":"Mondi A, Fabbiani M, Ciccarelli N, Colafigli M, D'Avino A, Borghetti A, Gagliardini R, Cauda R, de Luca A, di Giambenedetto S (2015) Efficacy and safety of treatment simplification to atazanavir\/ritonavir+lamivudine in HIV-infected patients with virological suppression: 144 week follow-up of the ATLAS pilot study. J Antimicrob Chemother 70:1843\u20131849","journal-title":"J Antimicrob Chemother"},{"issue":"11","key":"701_CR28","doi-asserted-by":"publisher","first-page":"1239","DOI":"10.1089\/aid.2010.0070","volume":"26","author":"RB Osih","year":"2010","unstructured":"Osih RB, Taff\u00e9 P, Rickenbach M, Gayet-Ageron A, Elzi L, Fux C, Opravil M, Bernasconi E, Schmid P, G\u00fcnthard HF, Cavassini M, Swiss HIV Cohort Study (2010) Outcomes of patients on dual-boosted PI regimens: experience of the Swiss HIV cohort study. AIDS Res Hum Retrovir 26(11):1239\u20131246","journal-title":"AIDS Res Hum Retrovir"},{"key":"701_CR29","doi-asserted-by":"publisher","first-page":"775","DOI":"10.1016\/S1473-3099(15)00097-3","volume":"15","author":"JA Perez-Molina","year":"2015","unstructured":"Perez-Molina JA, Rubio R et al (2015) GESIDA 7011 Study Group. Dual treatment with atazanavir-ritonavir plus two nucleos(t)ides in virologically stable patients with HIV-1 (SALT): 48 week results from a randomised, open-label, non-inferiority trial. Lancet Infect Dis 15:775\u2013784","journal-title":"Lancet Infect Dis"},{"issue":"9","key":"701_CR30","first-page":"1611","volume":"18","author":"C Power","year":"1985","unstructured":"Power C, Selnes OA et al (1985) HIV dementia scale: a rapid screening test. J Acquir Immune Defic Syndr Hum Retrovirol 18(9):1611\u20131616","journal-title":"J Acquir Immune Defic Syndr Hum Retrovirol"},{"issue":"7","key":"701_CR31","doi-asserted-by":"publisher","first-page":"590","DOI":"10.1016\/S1473-3099(14)70796-0","volume":"14","author":"A Pozniak","year":"2014","unstructured":"Pozniak A, Markowitz M, Mills A, Stellbrink HJ, Antela A, Domingo P, Girard PM, Henry K, Nguyen T, Piontkowsky D, Garner W, White K, Guyer B (2014) Switching to coformulated elvitegravir, cobicistat, emtricitabine, and tenofovir versus continuation of non-nucleoside reverse transcriptase inhibitor with emtricitabine and tenofovir in virologically suppressed adults with HIV (STRATEGY-NNRTI): 48 week results of a randomised, open-label, phase 3b, non-inferiority trial. Lancet Infect Dis 14(7):590\u2013599","journal-title":"Lancet Infect Dis"},{"issue":"55","key":"701_CR32","doi-asserted-by":"publisher","first-page":"3","DOI":"10.1111\/hiv.12440","volume":"17","author":"F Raffi","year":"2016","unstructured":"Raffi F, Esser S, Nunnari G, P\u00e9rez-Valero I, Waters L (2016) Switching regimens in virologically suppressed HIV-1-infected patients: evidence base and rationale for integrase strand transfer inhibitor (INSTI)-containing regimens. HIV Med 17(55):3\u201316","journal-title":"HIV Med"},{"key":"701_CR33","unstructured":"Reitan RM, Wolfson D (1985) The Halstead-Reitan. Neuropsychological Test Battery, Neuropsychological Press, Tucon"},{"issue":"7","key":"701_CR34","doi-asserted-by":"publisher","first-page":"713","DOI":"10.1080\/14656566.2018.1457648","volume":"19","author":"B Rossetti","year":"2018","unstructured":"Rossetti B, Montagnani F, de Luca A (2018) Current and emerging two-drug approaches for HIV-1 therapy in ART-na\u00efve and ART-experienced, virologically suppressed patients. Expert Opin Pharmacother 19(7):713\u2013738","journal-title":"Expert Opin Pharmacother"},{"key":"701_CR35","volume-title":"Symbol Digit Modalities Test (SDMT). Manual (revised)","author":"A Smith","year":"1982","unstructured":"Smith A (1982) Symbol Digit Modalities Test (SDMT). Manual (revised). Western Psychological Services, Los Angeles"},{"key":"701_CR36","unstructured":"Spreen O, Strauss E (2001) Controlled word association. A compendium of neuropsychological tests New York 2001. Oxford University Press, pp 221\u2013229"},{"key":"701_CR37","doi-asserted-by":"publisher","DOI":"10.7448\/IAS.17.4.19656","volume":"17","author":"IP Valero","year":"2014","unstructured":"Valero IP, Pasquau J et al (2014) CNS safety at 48-week of switching to ATAZANAVIR\/r plus lamivudine or two nucleos(t)ides in HIV suppressed patients on stable ART: the SALT neurocognitive substudy. J Int AIDS Soc 17:19656","journal-title":"J Int AIDS Soc"}],"container-title":["Journal of NeuroVirology"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s13365-018-0701-x.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/article\/10.1007\/s13365-018-0701-x\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s13365-018-0701-x.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2020,1,8]],"date-time":"2020-01-08T19:12:51Z","timestamp":1578510771000},"score":1,"resource":{"primary":{"URL":"http:\/\/link.springer.com\/10.1007\/s13365-018-0701-x"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2019,1,9]]},"references-count":37,"journal-issue":{"issue":"2","published-print":{"date-parts":[[2019,4]]}},"alternative-id":["701"],"URL":"https:\/\/doi.org\/10.1007\/s13365-018-0701-x","relation":{},"ISSN":["1355-0284","1538-2443"],"issn-type":[{"value":"1355-0284","type":"print"},{"value":"1538-2443","type":"electronic"}],"subject":[],"published":{"date-parts":[[2019,1,9]]},"assertion":[{"value":"8 September 2018","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"5 November 2018","order":2,"name":"revised","label":"Revised","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"9 November 2018","order":3,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"9 January 2019","order":4,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Compliance with ethical standards"}},{"value":"Gabriele Arendt received financial support from Janssen-Cilag GmbH, Germany and from ViiV Healthcare and honoraria for lectures and consultancies from Abbvie, Bristol-Myers Squibb, Gilead Sciences, Janssen-Cilag GmbH, Germany and MSD. All the other authors declare that they have no conflict of interest.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflicts of interest"}}]}}